E-Book, Englisch, 312 Seiten
Essential Infectious Disease Topics for Primary Care
1. Auflage 2008
ISBN: 978-1-60327-034-2
Verlag: Humana Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
E-Book, Englisch, 312 Seiten
ISBN: 978-1-60327-034-2
Verlag: Humana Press
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)
Autoren/Hrsg.
Weitere Infos & Material
1;Preface;6
2;Table of Contents;8
3;Contributors;10
4;Part I;13
4.1;Chapter 1;14
4.1.1;Clinical Guidelines;14
4.1.1.1;Overview and Epidemiology;14
4.1.1.2;Likely Pathogens in CAP;15
4.1.1.3;Chest Radiography;15
4.1.1.4;Other Diagnostic Testing;15
4.1.1.5;Specific Pathogen Testing;16
4.1.1.5.1;S. pneumoniae;16
4.1.1.5.2;Legionella Species;16
4.1.1.5.3;C. pneumoniae;17
4.1.1.5.4;Viral Pneumonia;17
4.1.1.5.5;Site of Treatment Decision;18
4.1.1.5.6;Empiric Therapy;18
4.1.1.6;Specific Antibacterial Agents;20
4.1.1.6.1;Macrolides;20
4.1.1.6.2;Ketolides;20
4.1.1.6.3;Amoxicillin;21
4.1.1.6.4;Amoxicillin-Clavulanate;21
4.1.1.6.5;Cephalosporins;21
4.1.1.6.6;Doxycycline;21
4.1.1.6.7;Fluoroquinolones;21
4.1.1.6.8;Clindamycin;22
4.1.1.7;Discharge Criteria;22
4.1.1.8;Special Populations and Circumstances;22
4.1.1.8.1;Pneumonia in Elderly Persons;22
4.1.1.8.2;Pneumonia in the Context of Bioterrorism;23
4.1.1.9;Update on Performance Indicators;24
4.1.1.10;Prevention;24
4.1.1.10.1;Influenza;24
4.1.1.10.2;Pneumococcal Vaccine;24
4.1.1.11;Selected Reading;25
4.2;Chapter 2;26
4.2.1;Pharyngitis;26
4.2.1.1;Introduction;26
4.2.1.2;Pathophysiology;27
4.2.1.3;Clinical Presentation;27
4.2.1.3.1;History;27
4.2.1.3.2;Physical Exam;27
4.2.1.3.3;Clinical Guidelines;28
4.2.1.4;Laboratory Evaluation;28
4.2.1.5;Differential Diagnosis;29
4.2.1.6;Treatment;30
4.2.1.7;Complications;31
4.2.1.8;Suggestions for Evaluation and Management;33
4.2.1.9;References;34
4.3;Chapter 3;36
4.3.1;Treatment and Management of Acute Otitis Media;36
4.3.1.1;Epidemiology and Risk Factors;36
4.3.1.2;Bacteriology and Vaccine Effects;37
4.3.1.3;Diagnosis of AOM;37
4.3.1.4;Treatment of Otitis Media;38
4.3.1.5;Observation Versus Immediate Treatment for AOM;38
4.3.1.6;Antibiotic Treatment of Otitis Media;39
4.3.1.6.1;Tympanostomy Tubes, Tympanostomy, and Adenoidectomy;41
4.3.1.7;Summary and Recommendations;41
4.3.1.8;References;42
4.4;Chapter 4;44
4.4.1;Management of Chronic Obstructive Pulmonary Disease Exacerbations and Acute Bronchitis;44
4.4.1.1;Chronic Obstructive Pulmonary Disease;44
4.4.1.1.1;Pathogenesis;44
4.4.1.1.2;Risk Factors;44
4.4.1.1.3;Diagnosis;45
4.4.1.1.4;Inpatient Versus Outpatient Management;46
4.4.1.1.5;Management;47
4.4.1.1.5.1;Supplemental Oxygen;47
4.4.1.1.5.2;Bronchodilator Therapy;47
4.4.1.1.5.3;Corticosteroid Therapy;47
4.4.1.1.5.4;Antibiotics;48
4.4.1.1.5.5;Noninvasive Positive Pressure Ventilation;49
4.4.1.1.5.6;Invasive Ventilation;49
4.4.1.1.5.7;Other Beneficial Treatments;51
4.4.1.1.6;Discharge Planning;51
4.4.1.2;Acute Bronchitis;51
4.4.1.2.1;Evaluation;52
4.4.1.2.2;Etiology;52
4.4.1.2.3;Management;52
4.4.1.3;References;53
4.5;Chapter 5;56
4.5.1;Latent Tuberculosis Infection;56
4.5.1.1;Introduction;56
4.5.1.2;Pathophysiology;57
4.5.1.3;Risk of Active TB;57
4.5.1.4;Screening for TB;58
4.5.1.5;Diagnosis of Active TB;58
4.5.1.6;Testing For TB;59
4.5.1.6.1;Positive Test Criterion;60
4.5.1.7;Other Diagnostic Tests;61
4.5.1.7.1;Chest Radiograph;61
4.5.1.7.2;Acid-Fast Bacilli Testing;62
4.5.1.7.3;Sputum Examination for AFB;62
4.5.1.7.4;Sputum Culture;62
4.5.1.7.5;Rapid Sputum Testing;63
4.5.1.7.6;Testing in Children;63
4.5.1.7.7;Treatment of LTBI;63
4.5.1.8;Special Considerations;66
4.5.1.9;References;66
4.6;Chapter 6;68
4.6.1;Acute Sinusitis;68
4.6.1.1;Introduction;68
4.6.1.2;Pathophysiology;68
4.6.1.3;Epidemiology;69
4.6.1.4;Clinical Presentation and Differential Diagnosis;69
4.6.1.5;Diagnosis;70
4.6.1.6;Treatment;72
4.6.1.6.1;Duration;73
4.6.1.6.2;Other Treatments;73
4.6.1.6.3;Nasal Steroids;74
4.6.1.7;Summary;74
4.6.1.8;Suggested Reading;75
5;Part II;76
5.1;Chapter 7;78
5.1.1;Gastroenteritis;78
5.1.1.1;Introduction;78
5.1.1.2;Pathophysiology;78
5.1.1.3;Clinical Presentation;90
5.1.1.3.1;History;90
5.1.1.3.2;Physical Exam;91
5.1.1.3.3;Laboratory Tests;92
5.1.1.3.4;Differential Diagnosis;92
5.1.1.4;Treatment;93
5.1.1.5;Conclusions;95
5.1.1.6;Suggested Reading;95
5.2;Chapter 8;96
5.2.1;Hepatitis;96
5.2.1.1;Introduction;96
5.2.1.2;Hepatitis A;96
5.2.1.2.1;Introduction;96
5.2.1.2.2;Pathophysiology;96
5.2.1.2.3;Clinical Presentation (History and Physical Exam);97
5.2.1.2.4;Laboratory Investigations;97
5.2.1.2.5;Differential Diagnosis and Differentiating Features;98
5.2.1.2.6;Treatment;99
5.2.1.2.7;Expected Outcomes and Complications;99
5.2.1.2.8;Prevention and Screening;99
5.2.1.3;Hepatitis B;100
5.2.1.3.1;Introduction;100
5.2.1.3.2;Pathophysiology;100
5.2.1.3.3;Clinical Presentation (History and Physical Exam);101
5.2.1.3.4;Laboratory Investigations;101
5.2.1.3.5;Differential Diagnosis;101
5.2.1.3.6;Treatment;103
5.2.1.3.7;Expected Outcomes and Complications;103
5.2.1.3.8;Prevention;103
5.2.1.4;Hepatitis C;104
5.2.1.4.1;Introduction;104
5.2.1.4.2;Pathophysiology;105
5.2.1.4.3;Clinical Presentation (History and Physical Exam);105
5.2.1.4.4;Laboratory Investigations;105
5.2.1.4.5;Differential Diagnosis and Differentiating Features-See Hepatitis A and B;107
5.2.1.4.5.1;Treatment;107
5.2.1.4.5.2;Expected Outcomes and Complication;107
5.2.1.4.5.3;Prevention;108
5.2.1.5;Hepatitis D;108
5.2.1.5.1;Introduction;108
5.2.1.5.2;Pathophysiology;109
5.2.1.5.3;Clinical Presentation (History, Physical Exam, and Laboratory Investigations);109
5.2.1.5.4;Treatment;110
5.2.1.5.5;Expected Outcomes and Complications;110
5.2.1.5.6;Prevention;110
5.2.1.6;Hepatitis E;111
5.2.1.6.1;Introduction;111
5.2.1.6.2;Pathophysiology;111
5.2.1.6.3;Clinical Presentation (History, Physical Exam, and Laboratory Investigations);111
5.2.1.6.4;Treatment;111
5.2.1.6.5;Expected Outcomes and Complications;111
5.2.1.6.6;Prevention;112
5.2.1.7;References;112
6;Part III;114
6.1;Chapter 9;116
6.1.1;Sexually Transmitted Diseases;116
6.1.1.1;Partner Management;116
6.1.1.2;Special Populations;117
6.1.1.2.1;Adolescents;117
6.1.1.2.2;Men Who Have Sex with Men;117
6.1.1.3;Detection of HIV Infection:Screening and Diagnostic Testing;117
6.1.1.4;Diseases Characterized by Genital Ulcers;118
6.1.1.4.1;Management of Patients Who Have Genital Ulcers;118
6.1.1.4.2;Chancroid;118
6.1.1.4.2.1;Diagnosis;118
6.1.1.4.2.2;Treatment;118
6.1.1.4.3;Genital HSV Infections;119
6.1.1.4.3.1;Diagnosis;119
6.1.1.4.3.2;Treatment;119
6.1.1.4.3.3;Severe Disease;121
6.1.1.4.3.4;Special Situations;121
6.1.1.4.4;Granuloma Inguinale (Donovanosis);122
6.1.1.4.4.1;Recommended Regimen;122
6.1.1.4.4.2;Alternative Regimens;122
6.1.1.4.4.3;Special Considerations;123
6.1.1.4.5;Lymphogranuloma Venereum;123
6.1.1.4.5.1;Treatment;124
6.1.1.4.5.2;Special Considerations;124
6.1.1.5;Syphilis;124
6.1.1.5.1;General Principles;124
6.1.1.5.1.1;Background;124
6.1.1.5.1.2;Serologic Testing;125
6.1.1.5.1.3;Treatment;125
6.1.1.5.1.4;Management of Sex Partners;125
6.1.1.5.2;Primary and Secondary Syphilis;126
6.1.1.5.2.1;Recommended Regimen for Adults;126
6.1.1.5.2.2;Other Management Considerations;126
6.1.1.5.2.3;Follow-Up;126
6.1.1.5.2.4;Special Considerations;126
6.1.1.5.3;Latent Syphilis;127
6.1.1.5.3.1;Treatment;127
6.1.1.5.4;Tertiary Syphilis;129
6.1.1.5.4.1;Recommended Regimen;129
6.1.1.5.4.2;Other Management Considerations;129
6.1.1.5.4.3;Special Considerations;129
6.1.1.5.5;Neurosyphilis;130
6.1.1.5.5.1;Treatment;130
6.1.1.5.5.2;Follow-Up;130
6.1.1.5.5.3;Special Considerations;131
6.1.1.5.6;Syphilis in HIV-Infected Persons;131
6.1.1.5.6.1;Diagnostic Considerations;131
6.1.1.5.6.2;Treatment;131
6.1.1.5.7;Primary and Secondary Syphilis in HIV-Infected Persons;131
6.1.1.5.7.1;Treatment;131
6.1.1.5.7.2;Other Management Considerations;132
6.1.1.5.7.3;Special Considerations;132
6.1.1.5.8;Latent Syphilis in HIV-Infected Persons;132
6.1.1.5.8.1;Diagnostic Considerations;132
6.1.1.5.8.2;Treatment;133
6.1.1.5.8.3;Special Considerations;133
6.1.1.5.9;Syphilis During Pregnancy;133
6.1.1.5.9.1;Diagnostic Considerations;133
6.1.1.5.9.2;Treatment;133
6.1.1.5.9.3;Recommended Regimen;134
6.1.1.5.9.4;Other Management Considerations;134
6.1.1.5.9.5;Follow-Up;134
6.1.1.5.9.6;Special Considerations;134
6.1.1.6;Diseases Characterized by Urethritis and Cervicitis;135
6.1.1.6.1;Management of Male Patients Who Have Urethritis;135
6.1.1.6.1.1;Etiology;135
6.1.1.6.1.2;Confirmed Urethritis;135
6.1.1.6.2;Management of Patients Who Have Nongonococcal Urethritis Diagnosis;136
6.1.1.6.2.1;Treatment;136
6.1.1.6.2.1.1;Recommended Regimens;136
6.1.1.6.2.1.2;Alternative Regimens;136
6.1.1.6.2.2;Follow-Up for Patients Who Have Urethritis;136
6.1.1.6.2.3;Recurrent and Persistent Urethritis;137
6.1.1.6.2.3.1;Recommended Regimens;137
6.1.1.6.3;Management of Patients Who Have Cervicitis;137
6.1.1.6.3.1;Etiology;137
6.1.1.6.3.2;Diagnosis;138
6.1.1.6.3.3;Treatment;138
6.1.1.6.3.3.1;Recommended Regimens for Presumptive Treatment;138
6.1.1.6.4;Management of Sex Partners;138
6.1.1.6.4.1;Special Considerations;139
6.1.1.6.4.1.1;HIV Infection;139
6.1.1.7;Chlamydial Infections;139
6.1.1.7.1;Chlamydial Infections in Adolescents and Adults;139
6.1.1.7.2;Diagnostic Considerations;139
6.1.1.7.3;Treatmen;139
6.1.1.7.3.1;Recommended Regimens;140
6.1.1.7.3.2;Alternative Regimens;140
6.1.1.7.3.3;Follow-Up;140
6.1.1.7.3.4;Management of Sex Partners;140
6.1.1.7.3.5;Special Considerations;141
6.1.1.7.3.6;Recommended Regimens;141
6.1.1.7.3.7;Alternative Regimens;141
6.1.1.8;Gonococcal Infections;142
6.1.1.8.1;Gonococcal Infections in Adolescents and Adults;142
6.1.1.8.2;Diagnostic Considerations;142
6.1.1.8.2.1;Dual Therapy for Gonococcal and Chlamydial Infections;142
6.1.1.8.3;Quinolone-Resistant N. gonorrhoeae;142
6.1.1.8.4;Uncomplicated Gonococcal Infections of the Cervix, Urethra, and Rectum;143
6.1.1.8.4.1;Recommended Regimens;143
6.1.1.8.4.2;Alternative Regimens;144
6.1.1.8.5;Uncomplicated Gonococcal Infections of the Pharynx;144
6.1.1.8.5.1;Recommended Regimens;144
6.1.1.8.5.2;Follow-Up;144
6.1.1.8.5.3;Management of Sex Partners;144
6.1.1.8.5.4;Special Considerations;145
6.1.1.8.6;Gonococcal Conjunctivitis;146
6.1.1.8.6.1;Recommended Regimen;146
6.1.1.8.7;Disseminated Gonococcal Infection;146
6.1.1.8.7.1;Treatment;146
6.1.1.8.8;Gonococcal Meningitis and Endocarditis;147
6.1.1.8.8.1;Recommended Regimen;147
6.1.1.9;Diseases Characterized by Vaginal Discharge;147
6.1.1.9.1;Management of Patients Who Have Vaginal Infections;147
6.1.1.9.2;Bacterial Vaginosis;148
6.1.1.9.3;Diagnostic Considerations;148
6.1.1.9.4;Treatment;148
6.1.1.9.4.1;Recommended Regimens;149
6.1.1.9.4.2;Alternative Regimens;149
6.1.1.9.5;Management of Sex Partners;150
6.1.1.9.5.1;Special Considerations;150
6.1.1.9.5.1.1;Allergy or Intolerance to the Recommended Therapy;150
6.1.1.9.5.1.2;Pregnancy;150
6.1.1.9.5.1.3;HIV Infection;151
6.1.1.9.5.2;Trichomoniasis;151
6.1.1.9.5.2.1;Recommended Regimens;152
6.1.1.9.5.2.2;Alternative Regimen;152
6.1.1.9.5.2.3;Follow-Up;152
6.1.1.9.5.2.4;Management of Sex Partners;152
6.1.1.9.5.2.5;Special Considerations;152
6.1.1.9.5.3;Vulvovaginal Candidiasis;153
6.1.1.9.5.3.1;Uncomplicated VVC;153
6.1.1.9.5.3.2;Complicated VVC;155
6.1.1.9.5.3.3;Severe VVC;156
6.1.1.9.5.3.4;Nonalbicans VVC;156
6.1.1.9.5.3.5;Compromised Host;156
6.1.1.9.5.3.6;Pregnancy;156
6.1.1.9.5.3.7;HIV Infection;156
6.1.1.9.5.4;Pelvic Inflammatory Disease;156
6.1.1.9.5.4.1;Diagnostic Considerations;157
6.1.1.9.5.4.2;Treatment;158
6.1.1.9.5.4.3;Parenteral Treatment;158
6.1.1.9.5.4.4;Oral Treatment;159
6.1.1.9.5.4.4.1;Follow-Up;160
6.1.1.9.5.4.4.2;Management of Sex Partners;161
6.1.1.9.5.4.4.3;Prevention;161
6.1.1.9.5.4.4.4;Special Considerations;161
6.1.1.9.5.5;Epididymitis;161
6.1.1.9.5.5.1;Diagnostic Considerations;162
6.1.1.9.5.5.2;Treatment;162
6.1.1.9.5.5.3;Management of Sex Partners;163
6.1.1.9.5.5.4;Special Considerations;163
6.1.1.9.5.6;HPV Infection;163
6.1.1.9.5.6.1;HPV Tests;163
6.1.1.9.5.6.2;Treatment;163
6.1.1.9.5.7;Genital Warts;164
6.1.1.9.5.7.1;Treatment;164
6.1.1.9.5.7.2;Counseling Genital HPV Infection;166
6.1.1.9.5.7.3;Management of Sex Partners;166
6.1.1.9.5.7.4;Special Considerations;167
6.1.1.10;Cervical Cancer Screening for Women Who Attend STD Clinics or Have a History of STDs;167
6.1.1.10.1;Vaccine Preventable STDs;167
6.1.1.10.1.1;Hepatitis A;167
6.1.1.10.1.1.1;Diagnosis;168
6.1.1.10.1.1.2;Treatment;168
6.1.1.10.1.1.3;Prevention;168
6.1.1.10.1.1.4;Preexposure Immunization;168
6.1.1.10.1.1.5;Prevaccination Serologic Testing for Susceptibility;168
6.1.1.10.1.1.6;Postvaccination Serologic Testing;168
6.1.1.10.1.1.7;Postexposure Prophylaxis;169
6.1.1.10.1.2;Hepatitis B;169
6.1.1.10.1.2.1;Diagnosis;169
6.1.1.10.1.2.2;Treatment;169
6.1.1.10.1.2.3;Prevention;169
6.1.1.10.1.2.4;Postexposure Prophylaxis;170
6.1.1.10.1.3;Hepatitis C;171
6.1.1.10.1.3.1;Proctitis, Proctocolitis, and Enteritis;171
6.1.1.10.1.3.1.1;Treatment;171
6.1.1.10.1.3.2;Ectoparasitic Infections;172
6.1.1.10.1.3.2.1;Pediculosis Pubis;172
6.1.1.10.1.3.2.1.1;Recommended Regimens;172
6.1.1.10.1.3.2.1.2;Alternative Regimens;172
6.1.1.10.1.3.2.1.3;Other Management Considerations;172
6.1.1.10.1.3.2.1.4;Follow-Up;173
6.1.1.10.1.3.2.1.5;Special Considerations;173
6.1.1.10.1.3.2.2;Scabies;173
6.1.1.10.1.3.2.2.1;Recommended Regimen;173
6.1.1.10.1.3.2.2.2;Alternative Regimens;173
6.1.1.10.1.3.2.2.3;Other Management Considerations;173
6.1.1.10.1.3.2.2.4;Crusted Scabies;173
6.1.1.10.1.3.2.2.5;Follow-Up;174
6.1.1.10.1.3.2.2.6;Management of Sex Partners and Household Contacts;174
6.1.1.10.1.3.2.2.7;Management of Outbreaks in Communities, Nursing Homes, and Other Institutional Settings;174
6.1.1.10.1.3.2.2.8;Special Considerations;174
6.1.1.10.1.3.3;Sexual Assault and STDs;174
6.1.1.10.1.3.3.1;Adults and Adolescents;174
6.1.1.10.1.3.3.2;Evaluation for Sexually Transmitted Infections Initial Examination;175
6.1.1.10.1.3.3.3;Follow-Up Examinations;175
6.1.1.10.1.3.3.4;Prophylaxis;175
6.1.1.10.1.3.3.5;Recommended Regimens;176
6.1.1.10.1.3.3.6;Risk for Acquiring HIV Infection;176
6.1.1.11;Bibliography;177
6.2;Chapter 10;178
6.2.1;Human Immunodeficiency Virus;178
6.2.1.1;Introduction;178
6.2.1.2;Pathophysiology;179
6.2.1.3;Clinical Presentation;179
6.2.1.4;OIs and Treatment;179
6.2.1.5;Differential Diagnosis;183
6.2.1.6;HIV Testing and Laboratory Studies;183
6.2.1.7;Treatment of HIV Infection;184
6.2.1.8;Development of Resistance and Treatment Failure;189
6.2.1.9;Pregnancy in the HIV-Positive Patient;190
6.2.1.10;Care of Infants and HIV-Positive Children;192
6.2.1.11;Postexposure Prophylaxis;192
6.2.1.12;Special Situations;196
6.2.1.13;Resources for Consultation;196
6.2.1.14;Bibliography;196
7;Part IV;198
7.1;Chapter 11;200
7.1.1;Cellulitis and Skin Infections Associated with Bites;200
7.1.1.1;Introduction;200
7.1.1.2;Cellulitis and Erysipelas;200
7.1.1.2.1;Pathophysiology;200
7.1.1.2.2;Bacteriology;201
7.1.1.2.3;Clinical Appearance and Differential Diagnosis;203
7.1.1.2.4;Invasive SSTI;203
7.1.1.2.4.1;Necrotizing Fasciitis;203
7.1.1.2.4.2;Pyomyositis;204
7.1.1.2.5;Noninfectious Conditions with Similar Appearance;204
7.1.1.2.5.1;Contact Dermatitis, Fixed Drug Reaction, Insect Bites, and Stings;205
7.1.1.2.5.2;Stasis Dermatitis;205
7.1.1.2.5.3;Wells Syndrome;205
7.1.1.2.5.4;Sweets Syndrome;205
7.1.1.2.5.5;Superficial Thrombophlebitis;205
7.1.1.2.5.6;Deep Venous Thrombosis;205
7.1.1.2.5.7;Acute Gouty Arthritis;205
7.1.1.2.5.8;Carcinoma Erysipelatoides;206
7.1.1.2.6;Diagnostic Studies;206
7.1.1.2.7;Treatment;206
7.1.1.2.8;Prevention of Recurrence;208
7.1.1.3;Skin Infections Associated with Bites;208
7.1.1.3.1;Dog and Cat Bites;209
7.1.1.3.1.1;Dog Bites;209
7.1.1.3.1.2;Cat Bite;209
7.1.1.3.1.3;Bacteriology;209
7.1.1.3.1.4;Initial Wound Management;209
7.1.1.3.1.5;Antibiotics;210
7.1.1.3.1.6;Immunization;210
7.1.1.3.2;Human Bites;211
7.1.1.3.2.1;Bacteriology;211
7.1.1.3.2.2;Wound Management and Antibiotics;211
7.1.1.4;References and Further Reading;212
7.2;Chapter 12;214
7.2.1;Diabetic Foot Infections;214
7.2.1.1;Introduction;214
7.2.1.2;Pathophysiology;214
7.2.1.3;Clinical Presentation;215
7.2.1.4;History;216
7.2.1.5;Physical Exam;216
7.2.1.6;Laboratory Investigations and Tests;217
7.2.1.7;Differential Diagnosis;219
7.2.1.8;Treatment;219
7.2.1.9;Expected Outcomes;222
7.2.1.10;Bibliography;222
7.3;Chapter 13;224
7.3.1;Osteomyelitis;224
7.3.1.1;Introduction;224
7.3.1.2;Pathophysiology;224
7.3.1.3;Acute Osteomyelitis;225
7.3.1.4;Chronic Osteomyelitis;226
7.3.1.5;Diagnosis;226
7.3.1.6;Laboratory Tests;227
7.3.1.7;Radiology;228
7.3.1.8;Treatment;229
7.3.1.9;Surgical Therapy;229
7.3.1.10;Medical Therapy;230
7.3.1.11;Hyperbaric Oxygen Therapy;231
7.3.1.12;Follow-Up;231
7.3.1.13;Prognosis;232
7.3.1.14;Prevention;232
7.3.1.15;Conclusion;233
7.3.1.16;References;233
7.4;Chapter 14;236
7.4.1;Septic Arthritis and Infectious Bursitis;236
7.4.1.1;Introduction;236
7.4.1.2;Background;236
7.4.1.3;Pathogenesis;237
7.4.1.4;Presentation;238
7.4.1.5;Diagnosis;239
7.4.1.6;Bacteriology;241
7.4.1.7;Treatment;242
7.4.1.8;Conclusion;244
7.4.1.9;References;244
7.5;Chapter 15;246
7.5.1;Lyme Disease Prevention, Diagnosis, and Treatment;246
7.5.1.1;Prevention and Prophylaxis;246
7.5.1.2;Diagnosis;247
7.5.1.3;Treatment of Early Lyme Disease;248
7.5.1.3.1;Lyme Meningitis and Other Manifestations of Early Neurologic Lyme Disease;248
7.5.1.4;Treatment of Late Lyme Disease;250
7.5.1.5;Post-Lyme Disease Syndromes;250
7.5.1.6;Summary and Recommendations;250
7.5.1.7;References;250
8;Part V;252
8.1;Chapter 16;254
8.1.1;Infective Endocarditis;254
8.1.1.1;Introduction;254
8.1.1.2;Pathophysiology;254
8.1.1.3;Clinical Presentation;256
8.1.1.4;Treatment;258
8.1.1.5;Complications;259
8.1.1.6;Antibiotic Prophylaxis;260
8.1.1.7;References;262
8.1.1.8;Suggested Reading;262
8.2;Chapter 17;264
8.2.1;Meningitis;264
8.2.1.1;Introduction;264
8.2.1.2;Pathophysiology;264
8.2.1.3;Clinical Presentation;265
8.2.1.4;Differential Diagnosis;266
8.2.1.5;Treatment;267
8.2.1.6;Outcome and Complications;268
8.2.1.7;Additional Information;269
8.2.1.8;Suggested Reading;269
8.3;Chapter 18;270
8.3.1;Urinary Tract Infections;270
8.3.1.1;Introduction;270
8.3.1.2;Pathophysiology;270
8.3.1.3;Clinical Presentation;272
8.3.1.3.1;History;272
8.3.1.3.1.1;Women;273
8.3.1.3.1.2;Men;273
8.3.1.3.1.3;Children;273
8.3.1.3.2;Physical Examination;274
8.3.1.3.2.1;Women;274
8.3.1.3.2.2;Men;274
8.3.1.3.2.3;Children;275
8.3.1.3.3;Diagnosis;275
8.3.1.3.3.1;Pregnant Women;277
8.3.1.3.3.2;Men;277
8.3.1.3.3.3;Children;277
8.3.1.3.4;Treatment;278
8.3.1.3.4.1;Asymptomatic Bacteriuria;278
8.3.1.3.4.2;Uncomplicated UTI;281
8.3.1.3.4.3;Complicated UTI;282
8.3.1.3.4.4;Pregnant Women;282
8.3.1.3.4.5;Men;283
8.3.1.3.4.6;Children;283
8.3.1.3.4.7;Follow-Up;284
8.3.1.4;References;284
8.4;Chapter 19;286
8.4.1;Adult Immunizations;286
8.4.1.1;Introduction;286
8.4.1.2;Hepatitis B;286
8.4.1.3;Hepatitis A;288
8.4.1.4;Measles, Mumps, and Rubella;289
8.4.1.5;Varicella and Zoster;290
8.4.1.5.1;Varicella;290
8.4.1.5.2;Zoster;291
8.4.1.6;Human Papillomaviruses;291
8.4.1.7;Pneumococcal Vaccine;292
8.4.1.8;Influenza Vaccine;293
8.4.1.9;Tetanus, Diphtheria, and Pertussis;294
8.4.1.10;Meningococcal Vaccine;296
8.4.1.11;Conclusion;297
8.4.1.12;References;297
8.5;Chapter 20;300
8.5.1;Clinical Ethics and Infectious Disease in Family Medicine;300
8.5.1.1;Introduction;300
8.5.1.2;Doesn’t the Law Resolve Most Bioethical Issues?;301
8.5.1.3;Won’t Professional Oaths and Codes Solve Ethical Issues?;301
8.5.1.4;A Framework:Case Analysis in Clinical Ethics;301
8.5.1.5;Case 1:No Harm in Asking;303
8.5.1.5.1;Step 1:Information Collection;303
8.5.1.5.2;Step 2:Ethical Evaluation;303
8.5.1.5.3;Step 3:Initiate Ethical Approach;305
8.5.1.5.4;Step 4:Review and Evaluate;305
8.5.1.6;Case 2:What We Don’t Know Can Hurt Us;306
8.5.1.6.1;Step 1:Information Collection;307
8.5.1.6.2;Step 2:Ethical Evaluation;308
8.5.1.6.3;Step 3:Initiate Ethical Approach;309
8.5.1.6.4;Step 4:Review and Evaluate Ethics;310
8.5.1.7;Summary;310
8.5.1.8;References;310
9;Index;312




